DeepMed Research

H. Lee Moffitt Cancer Center and Research Institute, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy

Phase 2

Active, not recruiting

Conditions: Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
Follicular Lymphoma
Diffuse Large-Cell Lymphoma
Transformed Follicular Lymphoma (TFL)
High-grade B-cell Lymphoma (HGBCL)

Interventions: Biological: Pneumococcal conjugate vaccine (PCV13)
Biological: CD19 targeted CAR T Cell Therapy

First Posted Date: 2021-02-09

Last Posted Date: 2025-03-17

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 26

Registration Number: NCT04745559

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

Early Phase 1

Recruiting

Conditions: Melanoma Stage III
Melanoma Stage IV
BRAF V600 Mutation

Interventions: Drug: Encorafenib Pill
Drug: Binimetinib Pill
Drug: Nivolumab

First Posted Date: 2021-02-05

Last Posted Date: 2025-05-22

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 50

Registration Number: NCT04741997

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML

Phase 1

Active, not recruiting

Conditions: Myelodysplastic Syndromes
Secondary Acute Myeloid Leukemia

Interventions: Biological: CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes
Drug: Standard of Care Chemotherapy

First Posted Date: 2020-11-09

Last Posted Date: 2025-04-11

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 19

Registration Number: NCT04620681

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC

Phase 1

Terminated

Conditions: Small-cell Lung Cancer
Relapsed Small Cell Lung Cancer
Recurrent Small Cell Lung Cancer

Interventions: Drug: Nivolumab
Drug: Ipilimumab
Drug: Lurbinectedin

First Posted Date: 2020-10-30

Last Posted Date: 2024-04-02

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 9

Registration Number: NCT04610658

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Advent Health - Celebration, Kissimmee, Florida, United States

Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC

Phase 1

Active, not recruiting

Conditions: Muscle-Invasive Bladder Carcinoma
Bladder Cancer

Interventions: Drug: CG0070
Drug: Nivolumab

First Posted Date: 2020-10-30

Last Posted Date: 2025-05-06

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 21

Registration Number: NCT04610671

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Evaluation of EnVisio SmartClip for Intraoperative Localization of Breast Masses

Completed

Conditions: Breast Cancer

Interventions: Device: EnVisio SmartClip
Device: EnVisio™ Navigation System

First Posted Date: 2020-10-27

Last Posted Date: 2025-03-14

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 50

Registration Number: NCT04604561

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

SARS-CoV-2 (COVID-19) Immune Surveillance Among a Population Based Sample of Adults in Florida

Completed

Conditions: Coronavirus Infection

Interventions: Diagnostic Test: SARS-CoV-2 Antibody Analysis
Diagnostic Test: Weck-cel Swab Collection
Behavioral: Web Based Questionnaire

First Posted Date: 2020-10-22

Last Posted Date: 2022-10-03

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 1135

Registration Number: NCT04596579

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Addressing Barriers to Palliative Care Use in Bladder Cancer

Completed

Conditions: Muscle-Invasive Bladder Carcinoma
Bladder Cancer Stage III
Bladder Cancer Stage II
Bladder Cancer Stage IV

Interventions: Other: Surveys

First Posted Date: 2020-10-22

Last Posted Date: 2023-01-03

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 54

Registration Number: NCT04598724

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

Phase 1

Recruiting

Conditions: HER2-positive Breast Cancer
Leptomeningeal Metastasis
Leptomeningeal Disease

Interventions: Radiation: Radiation Therapy
Drug: Pertuzumab
Drug: Trastuzumab

First Posted Date: 2020-10-19

Last Posted Date: 2025-04-17

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 39

Registration Number: NCT04588545

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Northwestern University, Evanston, Illinois, United States

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

Phase 2

Recruiting

Conditions: Melanoma Stage III
Melanoma Stage IV
Inoperable Disease

Interventions: Drug: Interleukin-2
Drug: Ipilimumab
Drug: Nivolumab

First Posted Date: 2020-09-24

Last Posted Date: 2025-03-17

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 29

Registration Number: NCT04562129

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy